Deal Talk EP2: Analysing NBIOs in Australian Public M&A

In Episode 2 of Deal Talk, partners Kam Jamshidi and Nicole Pedler explore what the 2025 NBIO market reveals for bidders and targets in Australian public M&A.HSF Kramer has deeply analysed non binding indicative offers in public deals to extract the key lessons for bidders and targets when formulating their M&A strategy. Drawing on this proprietary data, the episode examines when NBIOs most commonly emerge and what that means for listed companies facing major announcements, leadership changes and other market moving events.Kam and Nicole work through the 2025 NBIO landscape, covering:success ratesdisclosure practices and timingengagement periodsprivate equity dynamicspre bid stakesrecent Takeovers Panel developmentsA practical discussion for boards, management teams and advisers preparing for, advising on or responding to a potential public M&A approach.